Status:
TERMINATED
Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
While the gold standard of treatment in invasive bladder cancer is surgical removal of the bladder, it is well accepted that a reasonable alternative is an organ preserving approach. Bladder preservat...
Detailed Description
Patients opting for bladder conservation in Ottawa are currently treated using intra-arterial cisplatin and concurrent radiotherapy using 3D-Conformal radiotherapy. It has been recently reported that ...
Eligibility Criteria
Inclusion
- A pathological diagnosis of pure or predominantly transitional cell bladder carcinoma
- Adequate Hematology and biochemistry parameters
- Invasive or treatment refractory non-invasive transitional cell bladder carcinoma OR operable patients who prefer bladder preservation OR inoperable patients.
- No metastases on CT scan of chest
Exclusion
- Patient with contraindication to radical radiotherapy including inflammatory bowel disease or significant irritative bladder symptoms
- Contraindication to internal iliac arterial catheterization
- Prior pelvic radiotherapy for other malignancies
- Prior cytotoxic chemotherapy excepting intravesical agents
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00350688
Start Date
November 1 2005
End Date
April 1 2010
Last Update
April 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, Canada, K1H 8L6